Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment
Software to save years in research that aligns patients and treatments.
Oxford Genome Sciences Announces New Therapeutic Antibody Deal with Medarex
New agreement to drive the development of OGeS’ own pipeline of antibodies in cancer.
FDA Clears Genetic Lab Test for Warfarin Sensitivity
Research has shown that some of the unexpected response to warfarin depends on variants of two genes, CYP2C9 and VKORC1.
bioMerieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for new Breast Cancer Treatment
bioMerieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen.
Med BioGene Welcomes Renowned Expert to Lymphoma Collaboration
Med BioGene Inc. has welcomed Sandeep S. Dave, M.D. of Duke University to its lymphoma collaboration.
SRI International and Pentax Corporation Develop Biomarkers for Oncology Diagnostics
The ultimate goal of the collaboration is to develop medical diagnostic tools for therapeutic intervention in the treatment of cancer.
DxS Signs a License with DiagnoCure for its Scorpions® Technology
DiagnoCure will gain access to Scorpions for the development of their GCC-based molecular test for colorectal cancer.
IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA
IPSOGEN grants LabCorp non-exclusive rights to offer an assay for the diagnosis of a group of leukemias caused by JAK2 gene variations.
Eden Biodesign and Borean Pharma Sign Deal to Develop Therapeutic Candidate for the Treatment of Cancer
Eden will manufacture MBP-DC-SIGN for Borean to use in key preclinical studies.
Increased Risk for Arthritis and Lupus Tied to new Gene
Scientists identify a critical gene that increases a person’s risk for rheumatoid arthritis and systemic lupus and may be involved in other autoimmune diseases.